| Biomimetic proteolipid vesicles for targeting inflamed tissues R Molinaro, C Corbo, JO Martinez, F Taraballi, M Evangelopoulos, ... Nature materials 15 (9), 1037-1046, 2016 | 370 | 2016 |
| Management and potentialities of primary cancer cultures in preclinical and translational studies G Miserocchi, L Mercatali, C Liverani, A De Vita, C Spadazzi, F Pieri, ... Journal of translational medicine 15, 1-16, 2017 | 121 | 2017 |
| Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model L Mercatali, F La Manna, A Groenewoud, R Casadei, F Recine, ... International journal of molecular sciences 17 (8), 1375, 2016 | 104 | 2016 |
| Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas A De Vita, L Mercatali, F Recine, F Pieri, N Riva, A Bongiovanni, ... OncoTargets and therapy, 6233-6246, 2016 | 82 | 2016 |
| NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences G Tosi, L Bondioli, B Ruozi, L Badiali, GM Severini, S Biffi, A De Vita, ... Journal of Neural Transmission 118, 145-153, 2011 | 79 | 2011 |
| A biomimetic 3D model of hypoxia-driven cancer progression C Liverani, A De Vita, S Minardi, Y Kang, L Mercatali, D Amadori, ... Scientific reports 9 (1), 12263, 2019 | 78 | 2019 |
| Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma R Molinaro, JO Martinez, A Zinger, A De Vita, G Storci, N Arrighetti, ... Biomaterials science 8 (1), 333-341, 2020 | 69 | 2020 |
| Investigating the mechanobiology of cancer cell–ECM interaction through collagen-based 3D scaffolds C Liverani, L Mercatali, L Cristofolini, E Giordano, S Minardi, GD Porta, ... Cellular and molecular bioengineering 10, 223-234, 2017 | 62 | 2017 |
| Neurotrophic factors and neurodegenerative diseases: a delivery issue B Ruozi, D Belletti, L Bondioli, A De Vita, F Forni, MA Vandelli, G Tosi Int Rev Neurobiol 102, 207-247, 2012 | 50 | 2012 |
| Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer A De Vita, C Liverani, R Molinaro, JO Martinez, KA Hartman, C Spadazzi, ... Scientific reports 11 (1), 1-12, 2021 | 47 | 2021 |
| Next-generation sequencing approaches for the identification of pathognomonic fusion transcripts in sarcomas: the experience of the Italian ACC Sarcoma working group D Racanelli, M Brenca, D Baldazzi, F Goeman, B Casini, B De Angelis, ... Frontiers in Oncology 10, 489, 2020 | 46 | 2020 |
| First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma A Bongiovanni, N Riva, M Ricci, C Liverani, F La Manna, A De Vita, ... OncoTargets and therapy, 3613-3619, 2015 | 38 | 2015 |
| A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences A De Vita, S Vanni, G Miserocchi, V Fausti, F Pieri, C Spadazzi, C Cocchi, ... Biomedicines 10 (2), 372, 2022 | 37 | 2022 |
| The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in … A De Vita, F Recine, G Miserocchi, F Pieri, C Spadazzi, C Cocchi, S Vanni, ... Journal of Experimental & Clinical Cancer Research 40 (1), 165, 2021 | 37 | 2021 |
| Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives S Vanni, A De Vita, L Gurrieri, V Fausti, G Miserocchi, C Spadazzi, ... Therapeutic Advances in Medical Oncology 14, 17588359221093973, 2022 | 35 | 2022 |
| Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas F Recine, A Bongiovanni, N Riva, V Fausti, A De Vita, L Mercatali, ... OncoTargets and therapy 10, 1155, 2017 | 35 | 2017 |
| Myxofibrosarcoma primary cultures: molecular and pharmacological profile A De Vita, F Recine, L Mercatali, G Miserocchi, C Liverani, C Spadazzi, ... Therapeutic advances in medical oncology 9 (12), 755-767, 2017 | 33 | 2017 |
| The effect of everolimus in an in vitro model of triple negative breast cancer and osteoclasts L Mercatali, C Spadazzi, G Miserocchi, C Liverani, A De Vita, ... International journal of molecular sciences 17 (11), 1827, 2016 | 33 | 2016 |
| CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems C Liverani, L Mercatali, C Spadazzi, F La Manna, A De Vita, N Riva, ... Bone 66, 214-222, 2014 | 33 | 2014 |
| RANKL: A promising circulating marker for bone metastasis response T Ibrahim, M Ricci, E Scarpi, A Bongiovanni, R Ricci, N Riva, C Liverani, ... Oncology letters 12 (4), 2970-2975, 2016 | 32 | 2016 |
